Program
pegrizeprument
Also written as “VEL-101” and “FR104”.
Its studies are mostly in Arthritis, Rheumatoid, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Veloxis Pharmaceuticals | 21 open or running | phase 2since Nov 24, 2025 | Jan 25, 2022 | Oct 2028phase 2 · NCT07290777 |
| OSE Immunotherapeutics | 10 open or running | phase 1since May 20, 2016 | May 20, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2016First study: phase 1 study in Arthritis, RheumatoidNew to OSE ImmunotherapeuticsOSE Immunotherapeutics · NCT02800811 · 64 enrolled · Belgium
- Jan 25, 2022Veloxis Pharmaceuticals's first study: phase 1 study in Healthy VolunteersNew to Veloxis PharmaceuticalsVeloxis Pharmaceuticals · NCT05238493 · 60 enrolled · United States
- Nov 24, 2025Phase 2 study in Transplantation, KidneyPhase 2 reachedVeloxis Pharmaceuticals · NCT07290777 · 120 planned · United States
Ahead
- Oct 2028Primary completion: phase 2 study in Transplantation, KidneyVeloxis Pharmaceuticals · NCT07290777
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07290777Transplantation, Kidney · United States | 2 | Recruiting | Veloxis Pharmaceuticals | Oct 2028 | 120 |
| NCT05238493Healthy Volunteers · United States | 1 | Completed | Veloxis Pharmaceuticals | Jan 3, 2023 | 60 |
| NCT02800811Arthritis, Rheumatoid · Belgium | 1 | Completed | OSE Immunotherapeutics | Jun 2016 | 64 |
How it is read
Names in the registry
- “VEL-101”, 2 entries
- “FR104”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.